- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
The post Molecular Cancer Therapeutics: Improving Immune Checkpoint Blockade Efficacy in Melanoma Brain Metastases through Myddosomal inhibition with Emavusertib appeared first on Curis, Inc.
The post Washington University School of Medicine appeared first on Curis, Inc.
The post Mt Sinai Comprehensive Cancer Center appeared first on Curis, Inc.
The post Emavusertib in Combination With FOLFOX/PD-1 Inhibitor ± Trastuzumab as First-Line Treatment for Untreated Unresectable Gastric and Esophageal Cancer ASCO-GI 2026 Poster appeared first on Curis, Inc.
The post Clinical Outcomes of Emavusertib Added to Azacitidine and Venetoclax Combination Therapy ASH 2025 appeared first on Curis, Inc.